Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 02, 2026 07:30 ET | Source: GJLaw

California DOJ Issues Statement of Interest in Battle Against Sterling Pathology for Covid-19 Healthcare Billing Fraud-GJLaw

DOJ issues Statement of Interest in battle against Sterling Pathology Medical Group for alleged phantom COVID-19 tests and healthcare billing fraud
January 14, 2026 13:14 ET | Source: Asthma and Allergy Foundation of America

Amid COVID-19 Vaccine Confusion, New Tool Helps Guide Decision-Making

Washington, DC, Jan. 14, 2026 (GLOBE NEWSWIRE) -- The Asthma and Allergy Foundation of America (AAFA) announces the release of a new COVID-19 Vaccine Decision Aid, designed to help people...
November 05, 2025 15:20 ET | Source: Tevogen Bio Inc

Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID

This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk...
October 15, 2025 15:50 ET | Source: Tevogen Bio Inc

Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest

Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of...
September 02, 2025 15:06 ET | Source: Association of American Physicians and Surgeons

Harms from Modified mRNA COVID-19 Vaccines Discussed in the Journal of American Physicians and Surgeons

While mRNA biologics are a transformative frontier, modified mRNA COVID vaccines can disrupt every body system. Urgent scrutiny and acountability needed.
August 27, 2025 12:50 ET | Source: BioNTech SE

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1Shipping of the LP.8.1-adapted vaccine will...
August 14, 2025 16:47 ET | Source: Invivyd

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311 to Protect American Adults and Adolescents from COVID-19

Invivyd Aligns with U.S. FDA on Rapid Pathway to Full Approval (BLA) of Vaccine Alternative Monoclonal Antibody VYD2311
July 25, 2025 02:30 ET | Source: BioNTech SE

Pfizer und BioNTech erhalten positive CHMP-Empfehlung für an LP.8.1 angepassten COVID-19-Impfstoff in der Europäischen Union

Daten zeigten, dass der an LP.8.1 angepasste COVID-19-Impfstoff verglichen mit den COVID-19-Impfstoffformulierungen 2024-2025 eine verbesserte Immunantwort gegen derzeit vorherrschende und neu...
July 25, 2025 02:30 ET | Source: BioNTech SE

Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to...
July 21, 2025 07:05 ET | Source: Invivyd

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published in JAMA Oncology Underscore Severe Impact of COVID-19 on This Population

National Comprehensive Cancer Network® (NCCN®) Guidelines Recommend Monoclonal Antibodies for COVID-19 Prevention in People with Cancer; New Data Published